Cite
Hyporesponsiveness to Erythropoietin Therapy in Hemodialyzed Patients: Potential Role of Prohepcidin, Hepcidin, and Inflammation.
MLA
Malyszko, Jolanta, et al. “Hyporesponsiveness to Erythropoietin Therapy in Hemodialyzed Patients: Potential Role of Prohepcidin, Hepcidin, and Inflammation.” Renal Failure, vol. 31, no. 7, Aug. 2009, pp. 544–48. EBSCOhost, https://doi.org/10.1080/08860220903082606.
APA
Malyszko, J., Malyszko, J. S., & Mysliwiec, M. (2009). Hyporesponsiveness to Erythropoietin Therapy in Hemodialyzed Patients: Potential Role of Prohepcidin, Hepcidin, and Inflammation. Renal Failure, 31(7), 544–548. https://doi.org/10.1080/08860220903082606
Chicago
Malyszko, Jolanta, Jacek S. Malyszko, and Michal Mysliwiec. 2009. “Hyporesponsiveness to Erythropoietin Therapy in Hemodialyzed Patients: Potential Role of Prohepcidin, Hepcidin, and Inflammation.” Renal Failure 31 (7): 544–48. doi:10.1080/08860220903082606.